XENON PHARMACEUTICALS INC (XENE:NASDAQ)
$35.61 0.27 (0.764%)
Analysed XENON PHARMACEUTICALS INC (XENE:NASDAQ) News Sources
Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
21-09-2026
yahoo.com
Xenon stock lost 30%, but the FDA story is more complicated
22-09-2026
thestreet.com
Xenon Pharmaceuticals (XENE) Seeks Epilepsy Approval. Can its Drug Overcome a Depression Setback?
23-09-2026
yahoo.com
Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review
27-09-2026
marketbeat.com
Ian Mortimer Receives the 2026 Bloom Burton Award
29-09-2026
yahoo.com
Xenon's AZK Approval Path Unlikely to Be Hurt by Safety Issues, RBC Says
01-10-2026
yahoo.com
Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month
01-10-2026
stocktwits.com
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02-10-2026
yahoo.com
Xenon Pharmaceuticals (XENE) Stock May Still Look Above Fair Value On Its Research Pipeline
09-10-2026
yahoo.com
Why Xenon Pharmaceuticals (XENE) Is Getting Attention Now
09-10-2026
yahoo.com
What is the current price of XENON PHARMACEUTICALS INC (XENE:NASDAQ)?
The current price of XENON PHARMACEUTICALS INC (XENE:NASDAQ) is $35.61.
XENON PHARMACEUTICALS INC (XENE:NASDAQ) absolute price change since previous trading day?
The absolute price change of XENON PHARMACEUTICALS INC (XENE:NASDAQ) since the previous trading day is $0.27.
XENON PHARMACEUTICALS INC (XENE:NASDAQ) percentage price change since previous trading day?
The percentage price change of XENON PHARMACEUTICALS INC (XENE:NASDAQ) since the previous trading day is 0.764%.
What is the most recent average sentiment score for XENON PHARMACEUTICALS INC (XENE:NASDAQ)?
The most recent average sentiment score for XENON PHARMACEUTICALS INC (XENE:NASDAQ) is 59 out of 100.
What is the most recent average sentiment for XENON PHARMACEUTICALS INC (XENE:NASDAQ)?
The most recent sentiment for XENON PHARMACEUTICALS INC (XENE:NASDAQ) is .
SEC-8K** Filing Available For XENON PHARMACEUTICALS INC (XENE:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.